Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov enrollment closed later-stage tilt small index

Haemophilia A With Inhibitors: later-stage trial registry

A small indexed set (4 trials) with no open enrollment listed right now.

Corpus placement: #4,115 of 28,707 conditions by registered trial count.

4 US clinical trials · none currently recruiting · #4,115 of 28,707 conditions by registered trial count

Haemophilia A With Inhibitors: 4 US clinical trials tracked, none currently recruiting.

Haemophilia A With Inhibitors is the subject of 4 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 3 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Novo Nordisk A/S, running 4 of these trials.

Enrollment posture brief

Registry condition haemophilia-a-with-inhibitors

OPEN 0 | RECR 0% | LATE 3 | EARLY 1 | RANK #4115 | SPON 4

Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)

Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%Haemophilia A With Inhib (th…0%
Open-enrollment share among volume-matched conditions near Haemophilia A With Inhibitors

Haemophilia A With Inhibitors has no open enrollment in this registry pull (4 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Haemophilia A With Inhibitors on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Haemophilia A With Inhibitors is recruiting below its size-band peers.

    0 of 4 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 21Phase 33

Phase Distribution

PhaseTrial count
Phase 2 1
Phase 3 3

Top Sponsors

Novo Nordisk A/S 4 trials

Named interventions

Most-linked intervention names on Haemophilia A With Inhibitors records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

eptacog alfa (activated) Drug
1 trials
vatreptacog alfa (activated) Drug
1 trials
activated recombinant human factor VII Drug
1 trials
Concizumab Drug
1 trials
Mim8 Drug
1 trials

US sites by state

Facility locations filed on Haemophilia A With Inhibitors trials. A trial with sites in several states counts in each.

California 4 trials
Michigan 3 trials
Indiana 3 trials
Iowa 3 trials
Georgia 3 trials
Texas 2 trials
Tennessee 2 trials
Pennsylvania 2 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Haemophilia A With Inhibitors page

4 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • No Haemophilia A With Inhibitors trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Novo Nordisk A/S sponsors the most Haemophilia A With Inhibitors trials on record, review their full trial history before evaluating a specific study. See Novo Nordisk A/S's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Haemophilia A With Inhibitors condition card totals 4 registered trials; most-linked intervention eptacog alfa (activated); top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.